Human papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) positive girls and women

Trial Profile

Human papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) positive girls and women

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Feb 2016 Planned End Date changed from 15 Aug 2013 to 17 Feb 2017 as reported by ISRCTN: Current Controlled Trials record.
    • 26 Feb 2016 Status changed from completed to active, no longer recruiting as reported by ISRCTN:Current Controlled Trials record.
    • 15 Aug 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top